Search Results

Ionetix begins routine supply of astatine-211 in North America, expanding sources of isotopes for targeted alpha therapy

Ionetix, a U.S. medical isotope producer, recently announced that it has begun routine supply of astatine-211 (At-211) in North America. The company stated that this development expands the supply sources of At-211 and is expected to support its further application in preclinical research and clinical development. Ionetix noted that it believes it is the first non-academic commercial supplier of At-211 in the United States. Ionetix produces At-211 at its facility in Lansing, Michigan, leveraging its proprietary cyclotron technology. The company currently operates a 30 MeV cyclotron equipped with optimized target technology, aiming to support the production of clinical-grade At-211. The company stated that its production ca...

2026-09-02

Molecular Partners Advances DLL3 Radiopharmaceutical MP0712 to Higher Dose Cohort

Swiss clinical-stage biotechnology company Molecular Partners AG recently announced its business progress and financial results for the first half of 2026. The company stated that its DLL3-targeting radioactive DARPin therapy MP0712 has advanced to the second therapeutic dose level in a U.S. multicenter Phase 1/2a clinical study, and patient enrollment for the new dose cohort is currently underway. MP0712 is a radiopharmaceutical targeting the tumor-associated antigen DLL3, carrying a therapeutic alpha-emitting radionuclide lead-212 (Pb-212) payload, co-developed by Molecular Partners and Orano Med, primarily for small cell lung cancer and other neuroendocrine tumors. According to the company's disclosure, the first dose cohort of MP0712...

2026-08-26

University of South China team extracts high-purity medical alpha nuclide Lead-212 from rare earth slag

On August 20, it was learned from the University of South China that the team led by Professor Wei Yuezhou successfully separated and obtained high-purity alpha nuclide Lead-212 and its precursor nuclide Thorium-228 directly from rare earth slag, achieving the extraction of 158 microcuries of Lead-212/Bismuth-212 from kilogram-level rare earth slag in a single batch. The achievement recently passed the scientific and technological achievement appraisal meeting for the "Technology Development for Extracting Medical Alpha Nuclide Lead-212 and Thorium-228 from Radium Slag from Monazite Processing" organized by the China Isotope and Radiation Association. Experts unanimously agreed that the overall technology has reached internationally advanced level, with single-pass recovery rate reaching internationally leading level, which is expected to promote China's independent supply of medical alpha nuclides and ensure the security of the nuclear medical industry chain, with broad application prospects...

2026-08-21

Thor Medical Commences Commercial Supply with First Delivery of High-Purity Thorium-228 from AlphaOne

Thor Medical ASA announced on August 5 that it has completed the first customer delivery of high-purity thorium-228 (Th-228) from its AlphaOne production facility at the Herøya industrial park. This marks the first customer shipment following the facility's production start announced last week, and signifies AlphaOne's entry into the commercial supply phase. Thor Medical CEO Jasper Kurth stated that commercial production represents the beginning of the company's industrial-scale manufacturing, and the first customer delivery demonstrates the company's transition from capacity building to serving customers through its first industrial-scale facility. The company stated that as production capacity gradually ramps up, it will continue to meet the growing demand for high-purity isotopes in the targeted alpha therapy field...

2026-08-06

TerraPower Isotopes to Donate Actinium-225 via Oncidium Foundation to Support Cancer Treatment Accessibility

TerraPower Isotopes (TPI), a subsidiary of U.S. nuclear innovation company TerraPower, announced on July 29 that it will coordinate the donation of the rare medical isotope actinium-225 (Ac-225) through the Oncidium Foundation to support economically disadvantaged cancer patients in accessing targeted radionuclide therapy. The Oncidium Foundation is a non-profit organization dedicated to promoting global access to targeted radionuclide cancer treatments. Its RLT-Connect program aims to help financially challenged patients access relevant therapies, reducing treatment disparities caused by geographic and economic conditions. This donation also marks TPI's entry into Oncidium's collaborative ecosystem of radioisotope suppliers, medical practitioners...

2026-07-30